Suppr超能文献

B7-H4.Ig 通过调节 NOD 小鼠中的 Th17 细胞抑制 1 型糖尿病的发展。

B7-H4.Ig inhibits the development of type 1 diabetes by regulating Th17 cells in NOD mice.

机构信息

Department of Surgery, University of British Columbia, Vancouver, BC, Canada.

出版信息

Cell Immunol. 2013 Mar;282(1):1-8. doi: 10.1016/j.cellimm.2013.03.005. Epub 2013 Apr 4.

Abstract

Type 1 diabetes (T1D) is an autoimmune disease characterized by immunological destruction of insulin-producing pancreatic β-cells and subsequent hyperglycemia. The non-obese diabetic (NOD) mouse strain spontaneously develops a disease similar to human T1D and is commonly used as an animal model for studying this disease. We have previously shown that the administration of B7-H4-immunoglobulin fusion protein (B7-H4.Ig), a newly identified T-cell co-inhibitory signaling molecule, blocks the onset of diabetes in NOD mice. However, the mechanism(s) by which B7-H4 protects NOD mice from T1D is not fully understood. IL-17 is a pro-inflammatory cytokine, produced by Th17 cells, that activates T cells and other immune cells to produce a variety of cytokines and chemokines. Increasing evidence has shown that therapeutic agents targeting the IL-17 molecule or directly inhibiting IL-17-producing cells regulate autoimmune diabetes in NOD mice, suggesting that IL-17 is involved in the pathogenesis of this disease. In this study, we investigate whether B7-H4.Ig treatment inhibits the generation of Th17 cells which subsequently decreases IL-17 production and prevents the onset of T1D in NOD mice. Pre-diabetic female NOD mice were injected intraperitoneally with control mouse IgG or B7-H4.Ig starting at 4 weeks of age for 12 weeks. Our data showed that the frequency of Th17 cells in B7-H4.Ig-treated mice was significantly decreased. In addition, our data showed that B7-H4.Ig-treated mice had decreased levels of pro-inflammatory cytokines and Th17-associated cytokines, and an increased level of the potent Th17 inhibitor IFN-γ. To further investigate the effect of B7-H4.Ig on differentiation of Th17 cells, we co-cultured splenocytes with Th17-polarizing cytokines in the absence or presence of B7-H4.Ig. Our results indicated that splenocytes, under the Th17 driving conditions in the presence of B7-H4.Ig, had significantly decreased the numbers of Th17 cells compared to cells co-cultured in the absence of B7-H4.Ig. Together, this study suggests that blocking the generation of Th17 cells with the administration of B7-H4.Ig effectively inhibits the development of T1D in NOD mice.

摘要

1 型糖尿病(T1D)是一种自身免疫性疾病,其特征是胰岛β细胞的免疫破坏,随后发生高血糖。非肥胖型糖尿病(NOD)小鼠自发发展出类似于人类 T1D 的疾病,通常被用作研究这种疾病的动物模型。我们之前已经表明,B7-H4-免疫球蛋白融合蛋白(B7-H4.Ig)的给药,一种新鉴定的 T 细胞共抑制信号分子,可以阻止 NOD 小鼠糖尿病的发作。然而,B7-H4 保护 NOD 小鼠免受 T1D 的机制尚不完全清楚。IL-17 是一种促炎细胞因子,由 Th17 细胞产生,激活 T 细胞和其他免疫细胞产生各种细胞因子和趋化因子。越来越多的证据表明,针对 IL-17 分子的治疗剂或直接抑制产生 IL-17 的细胞调节 NOD 小鼠的自身免疫性糖尿病,表明 IL-17 参与了这种疾病的发病机制。在这项研究中,我们研究了 B7-H4.Ig 治疗是否抑制 Th17 细胞的生成,随后减少 IL-17 的产生并防止 NOD 小鼠 T1D 的发作。在 4 周龄时,将预糖尿病雌性 NOD 小鼠腹膜内注射对照小鼠 IgG 或 B7-H4.Ig,持续 12 周。我们的数据表明,B7-H4.Ig 治疗小鼠中 Th17 细胞的频率显着降低。此外,我们的数据表明,B7-H4.Ig 治疗小鼠的促炎细胞因子和 Th17 相关细胞因子水平降低,而强效 Th17 抑制剂 IFN-γ 的水平升高。为了进一步研究 B7-H4.Ig 对 Th17 细胞分化的影响,我们在不存在或存在 B7-H4.Ig 的情况下将脾细胞与 Th17 极化细胞因子共培养。我们的结果表明,在 Th17 驱动条件下存在 B7-H4.Ig 的情况下,与在不存在 B7-H4.Ig 的情况下共培养的细胞相比,脾细胞中 Th17 细胞的数量显着减少。总之,这项研究表明,用 B7-H4.Ig 给药阻断 Th17 细胞的生成可有效抑制 NOD 小鼠 T1D 的发展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验